Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome

Experimental Cell Research

Volumn 315, Issue 11, 2009, Pages 1850-1859

  Tandle, Anita T ^a   Calvani, Maura ^b   Uranchimeg, Badarch ^b   Zahavi, David ^a   Melillo, Giovanni ^b   Libutti, Steven K ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; EMAP II; HIF 1 ; Integrin receptor; Proteasome

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; VERY LATE ACTIVATION ANTIGEN 5;

ANGIOGENESIS; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; ENZYME DEGRADATION; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

EID: 67349132912     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.03.021     Document Type: Article

References (38)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
2. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 (2003) 685-693
3. Semenza G.L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15 (1999) 551-578
4. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev., Cancer 3 (2003) 721-732
5. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
6. Marignol L., Coffey M., Lawler M., and Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction?. Cancer Treat. Rev. 34 (2008) 313-327
7. Kao J., Ryan J., Brett G., Chen J., Shen H., Fan Y.G., Godman G., Familletti P.C., Wang F., Pan Y.C., Stern D., and Clauss M. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J. Biol. Chem. 267 (1992) 20239-20247
8. Berger A.C., Alexander H.R., Tang G., Wu P.S., Hewitt S.M., Turner E., Kruger E., Figg W.D., Grove A., Kohn E., Stern D., and Libutti S.K. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc. Res. 60 (2000) 70-80
9. Berger A.C., Alexander H.R., Wu P.C., Tang G., Gnant M.F., Mixon A., Turner E.S., and Libutti S.K. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II). Cytokine 12 (2000) 992-1000
10. van Horssen R., Eggermont A.M., and ten Hagen T.L. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev. 17 (2006) 339-348
11. Gnant M.F., Berger A.C., Huang J., Puhlmann M., Wu P.C., Merino M.J., Bartlett D.L., Alexander Jr. H.R., and Libutti S.K. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res. 59 (1999) 4668-4674
12. Crippa L., Gasparri A., Sacchi A., Ferrero E., Curnis F., and Corti A. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha. Cancer Res. 68 (2008) 1154-1161
13. van Horssen R., Rens J.A., Brunstein F., Guns V., van Gils M., Hagen T.L., and Eggermont A.M. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion. Int. J. Cancer 119 (2006) 1481-1490
14. Tandle A.T., Mazzanti C., Alexander H.R., Roberts D.D., and Libutti S.K. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine 30 (2005) 347-358
15. Baek J.H., Mahon P.C., Oh J., Kelly B., Krishnamachary B., Pearson M., Chan D.A., Giaccia A.J., and Semenza G.L. OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol. Cell 17 (2005) 503-512
16. Chang S.Y., Park S.G., Kim S., and Kang C.Y. Interaction of the C-terminal domain of p43 and the alpha subunit of ATP synthase. Its functional implication in endothelial cell proliferation. J. Biol. Chem. 277 (2002) 8388-8394
17. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., and Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002) 4316-4324
18. Calvani M., Rapisarda A., Uranchimeg B., Shoemaker R.H., and Melillo G. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107 (2006) 2705-2712
19. Schwarz M.A., Zheng H., Liu J., Corbett S., and Schwarz R.E. Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin. Exp. Cell Res. 311 (2005) 229-239
20. Cho S., Choi Y.J., Kim J.M., Jeong S.T., Kim J.H., Kim S.H., and Ryu S.E. Binding and regulation of HIF-1alpha by a subunit of the proteasome complex, PSMA7. FEBS Lett. 498 (2001) 62-66
21. Giaccia A.J., Simon M.C., and Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev. 18 (2004) 2183-2194
22. Hirota K., and Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol./Hematol. 59 (2006) 15-26
23. Francis S.E., Goh K.L., Hodivala-Dilke K., Bader B.L., Stark M., Davidson D., and Hynes R.O. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 927-933
24. Maeshima Y., Colorado P.C., and Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275 (2000) 23745-23750
25. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., and Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4766-4771
26. Sottile J., and Chandler J. Fibronectin matrix turnover occurs through a caveolin-1-dependent process. Mol. Biol. Cell 16 (2005) 757-768
27. Shi F., and Sottile J. Caveolin-1-dependent {beta}1 integrin endocytosis is a critical regulator of fibronectin turnover. J. Cell. Sci. 121 (2008) 2360-2371
28. Gerards W.L., de Jong W.W., Boelens W., and Bloemendal H. Structure and assembly of the 20S proteasome. Cell. Mol. Life Sci. 54 (1998) 253-262
29. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
30. Kallio P.J., Wilson W.J., O Brien S., Makino Y., and Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 274 (1999) 6519-6525
31. Sutter C.H., Laughner E., and Semenza G.L. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4748-4753
32. Schwarz M.A., Kandel J., Brett J., Li J., Hayward J., Schwarz R.E., Chappey O., Wautier J.L., Chabot J., Lo Gerfo P., and Stern D. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J. Exp. Med. 190 (1999) 341-354
33. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
34. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., and Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835
35. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., and Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16 (1996) 4604-4613
36. Manalo D.J., Rowan A., Lavoie T., Natarajan L., Kelly B.D., Ye S.Q., Garcia J.G., and Semenza G.L. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005) 659-669
37. Tang N., Wang L., Esko J., Giordano F.J., Huang Y., Gerber H.P., Ferrara N., and Johnson R.S. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 (2004) 485-495
38. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 4 (2006) 601-605